Ocugen (NASDAQ:OCGN) Receives “Buy” Rating from Chardan Capital

Ocugen (NASDAQ:OCGN)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a report issued on Thursday,Benzinga reports. They currently have a $7.00 price target on the stock. Chardan Capital’s price objective suggests a potential upside of 260.84% from the stock’s previous close.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.00.

Ocugen Stock Performance

Shares of NASDAQ OCGN opened at $1.94 on Thursday. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 8.04. Ocugen has a 12 month low of $0.52 and a 12 month high of $2.00. The stock has a 50 day moving average of $1.57 and a 200-day moving average of $1.42. The company has a market capitalization of $605.87 million, a P/E ratio of -8.82 and a beta of 2.75.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). Ocugen had a negative return on equity of 491.22% and a negative net margin of 1,192.18%.The business had revenue of ($0.19) million for the quarter, compared to analysts’ expectations of $0.86 million. As a group, equities research analysts predict that Ocugen will post -0.2 EPS for the current year.

Institutional Trading of Ocugen

Institutional investors have recently bought and sold shares of the business. UBS Group AG grew its position in shares of Ocugen by 373.2% during the 4th quarter. UBS Group AG now owns 4,849,353 shares of the company’s stock worth $6,547,000 after purchasing an additional 3,824,474 shares in the last quarter. State Street Corp raised its position in shares of Ocugen by 193.6% in the fourth quarter. State Street Corp now owns 3,978,738 shares of the company’s stock valued at $5,371,000 after buying an additional 2,623,361 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Ocugen in the fourth quarter valued at approximately $3,417,000. Goldman Sachs Group Inc. grew its position in Ocugen by 2,256.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,302,475 shares of the company’s stock worth $3,108,000 after buying an additional 2,204,765 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Ocugen by 485.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,700,400 shares of the company’s stock worth $2,296,000 after buying an additional 1,410,200 shares in the last quarter. Institutional investors own 10.27% of the company’s stock.

Key Headlines Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Completed enrollment in the OCU400 Phase 3 liMeliGhT registrational trial, with topline Phase 3 data expected in Q1 2027 — a clear regulatory milestone that advances OCU400 toward potential approval in 2027. Read More.
• Positive Sentiment: Management outlined a plan for a 2026 BLA submission and said it expects three pivotal filings within three years, alongside leadership expansion — signaling an accelerated regulatory and clinical push that could materially re-rate the equity if filings and readouts succeed. Read More.
• Positive Sentiment: Market/media reaction included headlines of “gains on results,” reflecting investor enthusiasm around recent clinical progress and messaging from management. This positive sentiment is likely why the shares received upward pressure earlier in the session. Read More.
• Neutral Sentiment: Management hosted the Q4 2025 earnings call and provided operational detail and Q&A; the call reiterated pipeline timelines (including OCU400) and discussed financial runway but added limited new near-term revenue catalysts. Read More.
• Negative Sentiment: Q4 financials disappointed on revenue and showed continued losses — reported EPS of ($0.06) matched estimates, but revenue missed expectations (reported near zero/negative revenue vs. analyst estimates) and net margin/ROE remain deeply negative, highlighting ongoing cash burn and execution risk. Read More.
• Negative Sentiment: Coverage outlets flagged the revenue shortfall and persistent quarterly loss, underscoring that until clinical milestones convert to approvals or partnerships, valuation hinges on successful trial outcomes and funding prospects. Read More.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.